869 related articles for article (PubMed ID: 16296764)
1. Strategies to improve oral drug bioavailability.
Gomez-Orellana I
Expert Opin Drug Deliv; 2005 May; 2(3):419-33. PubMed ID: 16296764
[TBL] [Abstract][Full Text] [Related]
2. Diverse approaches for the enhancement of oral drug bioavailability.
Fasinu P; Pillay V; Ndesendo VM; du Toit LC; Choonara YE
Biopharm Drug Dispos; 2011 May; 32(4):185-209. PubMed ID: 21480294
[TBL] [Abstract][Full Text] [Related]
3. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
Dahan A; Hoffman A
J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
[TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
5. Buccal bioadhesive drug delivery--a promising option for orally less efficient drugs.
Sudhakar Y; Kuotsu K; Bandyopadhyay AK
J Control Release; 2006 Aug; 114(1):15-40. PubMed ID: 16828915
[TBL] [Abstract][Full Text] [Related]
6. [Research of oral prodrugs: opportunities and challenges].
Cao F; Ping QN; Chen J
Yao Xue Xue Bao; 2008 Apr; 43(4):343-9. PubMed ID: 18664193
[TBL] [Abstract][Full Text] [Related]
7. Prodrug approaches for enhancing the bioavailability of drugs with low solubility.
Müller CE
Chem Biodivers; 2009 Nov; 6(11):2071-83. PubMed ID: 19937841
[TBL] [Abstract][Full Text] [Related]
8. Approaches towards enhanced transepithelial drug delivery.
Majumdar S; Mitra AK
Discov Med; 2006 Dec; 6(36):229-33. PubMed ID: 17250788
[TBL] [Abstract][Full Text] [Related]
9. When poor solubility becomes an issue: from early stage to proof of concept.
Stegemann S; Leveiller F; Franchi D; de Jong H; Lindén H
Eur J Pharm Sci; 2007 Aug; 31(5):249-61. PubMed ID: 17616376
[TBL] [Abstract][Full Text] [Related]
10. In vitro - in vivo correlation: from theory to applications.
Emami J
J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
[TBL] [Abstract][Full Text] [Related]
11. Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development.
Majumdar S; Duvvuri S; Mitra AK
Adv Drug Deliv Rev; 2004 Jun; 56(10):1437-52. PubMed ID: 15191791
[TBL] [Abstract][Full Text] [Related]
12. [Endocytosis mediated by receptors--function and participation in oral drug delivery].
Zuwała-Jagiełło J
Postepy Hig Med Dosw; 2003; 57(3):275-91. PubMed ID: 14524247
[TBL] [Abstract][Full Text] [Related]
13. The utility of cyclodextrins for enhancing oral bioavailability.
Carrier RL; Miller LA; Ahmed I
J Control Release; 2007 Nov; 123(2):78-99. PubMed ID: 17888540
[TBL] [Abstract][Full Text] [Related]
14. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs.
Kawakami K
Adv Drug Deliv Rev; 2012 May; 64(6):480-95. PubMed ID: 22265844
[TBL] [Abstract][Full Text] [Related]
15. Oral osmotically driven systems: 30 years of development and clinical use.
Malaterre V; Ogorka J; Loggia N; Gurny R
Eur J Pharm Biopharm; 2009 Nov; 73(3):311-23. PubMed ID: 19602438
[TBL] [Abstract][Full Text] [Related]
16. Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats.
Choi JS; Shin SC
Int J Pharm; 2005 Mar; 292(1-2):149-56. PubMed ID: 15725561
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in intravenous delivery of poorly water-soluble compounds.
Shi Y; Porter W; Merdan T; Li LC
Expert Opin Drug Deliv; 2009 Dec; 6(12):1261-82. PubMed ID: 19941409
[TBL] [Abstract][Full Text] [Related]
18. Industrial perspective in ocular drug delivery.
Ali Y; Lehmussaari K
Adv Drug Deliv Rev; 2006 Nov; 58(11):1258-68. PubMed ID: 17079049
[TBL] [Abstract][Full Text] [Related]
19. Rapidly disintegrating oramucosal drug delivery technologies.
Reddy D; Pillay V; Choonara YE; du Toit LC
Pharm Dev Technol; 2009; 14(6):588-601. PubMed ID: 19883248
[TBL] [Abstract][Full Text] [Related]
20. What should be considered on design of a colon-specific prodrug?
Jung Y; Kim YM
Expert Opin Drug Deliv; 2010 Feb; 7(2):245-58. PubMed ID: 20095945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
